Clinical Progress in Pancreatic Cancer Therapy Unveiled Next Week in London
Silenseed present exclusive clinical evidence on the effectiveness of siRNA against mutated KRAS in pancreatic cancer at RNA Therapeutics 2016
London, United Kingdom, February 11, 2016 --(PR.com)-- SMi Group are delighted to announce a new speaker for the two day event which will gather some of the most internationally prominent senior scientists and drug delivery experts next week.
Amtoz Shemi, Chief Executive Officer from clinical stage biopharmaceutical company, Silenseed, will join the stellar line-up at the RNA Therapeutics conference taking place on 15th & 16th February 2016 in London, UK.
Through a case study driven address, the presentation entitled: RNAi and Tumor Microenvironment, will reveal clinical findings on the effectiveness of siRNA against mutated KRAS in pancreatic cancer. Amtoz Shemi will highlight how prolonged continues release of siRNA modifies tumor microenvironment can accelerate drug distribution and discuss developments for delivery of RNAi-based drugs.
Attendees at the 7th annual show will also be invited to share their thoughts in 2 interactive panel sessions and gain knowledge from industry specialists to identify cutting-edge developments in supporting RNA therapeutics in treatment. Key insights will be given into gene expression with oligonucleotides, mRNA technology, multi-functional nanoparticle carriers and targeted delivery through ligand-conjugate chemistry.
Featured speakers include:
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
Nagy Habib, Professor of Surgery, Chairman & Co-founder Imperial College London, MiNA Therapeutics
Dr Kai Williams, Senior Director Europe, Advanced Cell Diagnostics
Mustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AG
Christian Schetter, Chief Executive Office and Managing Director, Rigontech GmbH
Cristianne Rijcken, CSO, Cristal Therapeutics
Nigel Horscroft, Director Alliance Management, Curevac
Claude Paul Malvy, Co-Head of Research Group: Chemical Vectorology of Anticancer Drugs, Gustave Roussy Institute
The full speaker line up, brochure and a preliminary list of attendees is available to download online at www.therapeutics-rna.com/prcom
7th Annual RNA Therapeutics Conference
15-16 February 2016
Holiday Inn Kensington Forum, London UK
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Amtoz Shemi, Chief Executive Officer from clinical stage biopharmaceutical company, Silenseed, will join the stellar line-up at the RNA Therapeutics conference taking place on 15th & 16th February 2016 in London, UK.
Through a case study driven address, the presentation entitled: RNAi and Tumor Microenvironment, will reveal clinical findings on the effectiveness of siRNA against mutated KRAS in pancreatic cancer. Amtoz Shemi will highlight how prolonged continues release of siRNA modifies tumor microenvironment can accelerate drug distribution and discuss developments for delivery of RNAi-based drugs.
Attendees at the 7th annual show will also be invited to share their thoughts in 2 interactive panel sessions and gain knowledge from industry specialists to identify cutting-edge developments in supporting RNA therapeutics in treatment. Key insights will be given into gene expression with oligonucleotides, mRNA technology, multi-functional nanoparticle carriers and targeted delivery through ligand-conjugate chemistry.
Featured speakers include:
Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
Nagy Habib, Professor of Surgery, Chairman & Co-founder Imperial College London, MiNA Therapeutics
Dr Kai Williams, Senior Director Europe, Advanced Cell Diagnostics
Mustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AG
Christian Schetter, Chief Executive Office and Managing Director, Rigontech GmbH
Cristianne Rijcken, CSO, Cristal Therapeutics
Nigel Horscroft, Director Alliance Management, Curevac
Claude Paul Malvy, Co-Head of Research Group: Chemical Vectorology of Anticancer Drugs, Gustave Roussy Institute
The full speaker line up, brochure and a preliminary list of attendees is available to download online at www.therapeutics-rna.com/prcom
7th Annual RNA Therapeutics Conference
15-16 February 2016
Holiday Inn Kensington Forum, London UK
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 (0) 207 827 6162
http://www.therapeutics-rna.com/prcom
Teri Arri
+44 (0) 207 827 6162
http://www.therapeutics-rna.com/prcom
Contact
Categories